Altmetrics
Downloads
133
Views
65
Comments
0
A peer-reviewed article of this preprint also exists.
supplementary.zip (4.30MB )
This version is not peer-reviewed
Submitted:
27 July 2023
Posted:
31 July 2023
You are already at the latest version
Mutation |
Cell Type(s) Affected |
Mechanism of immunodeficiency | Clinical implications and treatments | ||
Developmental deficiencies | |||||
DiGeorge Syndrome | 22q11.2 deletion | T cells | Small or no thymus, low T cell counts. | Hematopoietic stem cell transplant or thymus transplant (in infancy) may be necessary | [36,37] |
Omenn Syndrome | Mutation in RAG1 or RAG2 | T and B cells | Diminished lymphocyte activation receptor variability, low B cell counts, defective negative selection in thymus (Normal-high T cell counts) | Elevated IgE levels, predisposition to autoimmunity | [38,39] |
Adenosine Deaminase (ADA) deficiency | Limited to no ADA expression (ADA is normally expressed in the thymus at high levels) | All lymphocytes, but mainly T cells | Depletion of developing lymphocytes via toxic accumulation of 2′deoxyadenosine and 2′dioxyinoside | Can result in severe combined immunodeficiency (SCID), and increased susceptibility to viral infections. | [40] |
Cartilage Hair Hypoplasia | RMRP gene mutation, important in RNA processing | All lymphocytes, but mainly T cells | Limited T cell maturation and differentiation, increased T cell apoptosis | Can result in SCID and a form of dwarfism, may have decreased antibody levels. | [41] |
Receptor deficiencies leading to pathophysiological activation: | |||||
CD25 deficiency | Mutation in IL2RA gene (α chain of IL-2 receptor) | T cells | Limited T cell development, proliferation, and activation, diminished IL-10 production (normal B cells) | Can result in SCID | [42,43] |
X-linked lymphoproliferative syndrome-1 (XLP1) | Mutation in signaling lymphocyte associated molecule (SLAM)- associated protein (SAP) | Lymphocytes | Limited T cell help and cytotoxicity, limited NK cell function | Increased incidence of lymphoma. HSCT is needed to cure | [44] |
MHCII Deficiency (Bare lymphocyte syndrome) | MHCII gene intact, mutations in genes regulating MHC transcription | CD4+ T cells and APCs | Reduced CD4+ T cell counts due to incomplete maturation from perturbed positive and negative selection in thymus | Persistent viral infections. HSCT is needed to cure | [45] |
Hyper IgM Syndrome | Mutation of CD40 on CD4+ T cells, or CD40L on B cells | CD4+ T cells and B cells | B cells cannot class switch out of IgM due to no CD40/CD40L interactions with CD4+ T cells | Increased bacterial infections, increased serum IgM levels. HSCT may be used to treat. | [46] |
Chronic Mucocutaneous Candidiasis | Many causes, some include RORγT or IL-17 receptor deficiency | Th17 cells | Limited to no differentiation into Th17 cells and limited anti-fungal immunity | Chronic candida fungus infection, treatments may include antifungals. HSCT may be used to cure | [47] |
Cytoskeletal defects that lead to pathophysiological migration and activation: | |||||
Wiskott-Aldrich Syndrome | Dysfunctional Wiskott-Aldrich syndrome protein (WASp) | All lymphocytes, but mainly T cells | Inability of lymphocytes to create branched actin filaments, critical for immune cell migration and TCR activation. | Limited CD8+ T cell and B cell function, both from intrinsic defects and restricted CD4+ T cell help | [48,49] |
Wiskott-Aldrich Syndrome-2 | WIPF1 gene mutation- WIP protein mutation (WASP-interacting protein) | Mainly T cells | Defective F-actin polymerization, leading to limited T cell migration and TCR activation. Low B and CD8+ T cell counts | Similar presentation to Wiskott-Aldrich Syndrome | [50] |
DOCK2 deficiency | DOCK2 | Hematopoietic cells, but mainly T cells | Limited Rac1 activation in T cells, reduced F actin polymerization | Possible decreased antibody production, decreased antiviral response. HSCT is needed to cure | [51] |
DOCK8 Deficiency | Deficient DOCK8 protein (Normally, DOCK8 interacts with Cdc42, leading to branched actin creation) | All lymphocytes, but mainly T cells | Limited T cell migration, activation, and proliferation. | Severe allergic responses, elevated IgE levels, high risk for skin infections. HSCT is necessary to cure | [52] |
NCKAP1 gene mutation | HEM1 protein (part of WAVE complex) | All immune cells, but mainly T cells and NK cells | Limited leading edge actin polymerization and migration, diminished immune synapse formation | Hyperinflammation, autoimmunity, recurring infections. May be treated with corticosteroids | [53,54] |
ARPC1B Deficiency | ARPC1B (assists ARP2/3 complex) | Hematopoietic cells | No immune synapse formation in T cells, limited migration | Autoimmunity, combined immunodeficiency | [55,56] |
CORO1A mutation | CORO1A C-terminal domain truncation | Hematopoietic cells, but mainly T cells | Inability for CORO1A to depolymerize actin cytoskeleton, leading to increased F-actin accumulation. Decreased T cell help | Limited CD4+ T cells, chronic viral infections, similar presentation to Wiskott-Aldrich syndrome | [57] |
CDC42 Deficiency | CDC42 | T cells and B cells | Impaired antibody production and T cell effectors function | Decline in T cell numbers and function, can treat some opportunistic infections with antibiotic prophylaxis | [58] |
RAC2 Deficiency | RAC2 | Hematopoietic cells | Decreased naïve CD4+ T cells, decreased neutrophil chemotaxis | Recurrent infections. HSCT can be used to cure | [59] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated